

JPET # 257071

Blood Pharmacokinetics Imaging by Non-invasive Heart Fluorescence Tomography and Application to Kidney Glomerular Filtration Rate Assessment

Authors: Bagna Bao, Kristine O. Vasquez, Guojie Ho, Jun Zhang, Jeannine Delaney, Milind Rajopadhye, and Jeffrey D. Peterson

Affiliations: BB, KOV, GH, JZ, JD, MR & JDP, PerkinElmer, Inc, 68 Elm Street, Hopkinton MA 01748

JPET # 257071

Running title: Tomographic Heart Imaging for PK and GFR Assessment

Corresponding Author Contact Information:

Jeffrey D. Peterson, Ph.D.

PerkinElmer Discovery & Analytical Sciences

68 Elm Street, Hopkinton MA 01748

Phone: (508) 589-7542

jeff.peterson@perkinelmer.com

text pages: 31

tables: 1

figures: 7

references: 38

words: 247 abstract

741 introduction

1976 materials and methods

1864 results

1121 discussion

List of abbreviations: FMT, fluorescence molecular tomography; NIR, near infrared; PK, pharmacokinetics; GFR, glomerular filtration rate

Recommended section: Drug Discovery and Translational Medicine

ABSTRACT

In mouse pharmacokinetic (PK) studies, current standard methods often require large numbers of animals to support collection of blood samples serially over a defined time range. We have developed and validated a non-invasive fluorescence molecular tomography (FMT) heart imaging approach for blood PK quantification that uses small numbers of mice and has the advantage of repeated, longitudinal live imaging. This method was validated using a variety of near infrared (NIR) fluorescent-labeled molecules, ranging in size from 1.3 to 150 kDa, that were assessed by microplate blood assays as well as by non-invasive FMT[®]4000 imaging. Excellent agreement in kinetic profiles and calculated PK metrics was seen for the two methods, establishing the robustness of this non-invasive optical imaging approach. FMT heart imaging was further assessed in the challenging application of inulin-based glomerular filtration rate (GFR) measurement. After a single bolus injection of an NIR fluorescent-labeled inulin probe in small cohorts of mice (n = 5 per group), two-minute heart scans (at 2, 6, 15, 30, and 45 minutes) were performed by FMT imaging. GFR was calculated using two-compartment PK modeling, determining an average rate of 240 ± 21 $\mu\text{L}/\text{min}$ in normal mice, in agreement with published mouse GFR ranges. Validation of GFR assessment in unilaterally nephrectomized mice and cyclosporin A (CsA)-treated mice both measured ~50% decreases in GFR. Imaging results correlated well with *ex vivo* plasma microplate assays for inulin blood kinetics, and the decreases in GFR were accompanied by increases in plasma creatinine and blood urea nitrogen.

Introduction

The optimization and characterization of small molecule drugs and large biomolecule therapeutics (or “biologics”) is a multifaceted process requiring the generation of extensive *in vitro* and *in vivo* research datasets. Characterizing agent blood pharmacokinetics (PK) and exposure profiles in animals is an important part of this process, providing guidance for formulation, optimization of bioavailability and clearance, establishing dosing regimens, determining the projected human dose (Toon, 1996), and understanding the pharmacodynamic/pharmacodynamic (PK/PD) relationship.

In early drug discovery, preclinical PK studies are often performed in mice for a direct comparison of PK and PD responses in mouse efficacy models. Unfortunately, the small body size of mice limits the amounts of blood available for analytical measurements of drug and PD marker levels. This is particularly an issue for large molecule biologics, which often require collection of large blood samples for ligand-binding immunoassays, large cohorts of mice, larger amounts of drug material, and more labor resources. As a result, PK studies in mice are typically low-throughput and high-resource efforts. In 2011, we used fluorescence tomography by FMT imaging for measuring whole body 3D imaging biodistribution in mice (Vasquez et al., 2011) and discovered that the longitudinal heart datasets agreed well with more labor-intensive microplate plasma assay results. One obvious advantage of the FMT heart PK approach is the ability to acquire full kinetic blood curves from individual mice through longitudinal live imaging, an approach that generally needs only 3-5 injected mice. There are certainly other non-imaging blood microsampling approaches (e.g. NanoDrop and LC-MS-MS analysis of dried blood spots (DBS)), that require collection of only small blood samples with few mice (Zhang et al., 2016). However, such approaches may still require extensive sample manipulation and analytical runs, whereas FMT heart imaging requires no sample collection and only minimal analysis for near real-time results. The mice can also be retained for weeks to repeat GFR assessment for longitudinal kidney toxicity studies. This is a potentially major benefit both logistically and ethically, supporting current world-wide initiatives in the 3Rs (reduce, refine and replace) of animal welfare (Balls, 2015).

To further validate FMT heart imaging for PK studies, we used a variety of NIR fluorescent-labeled agents, ranging in molecular weight from 1.3 to 150 kDa. A careful comparison of 1.6 kDa FolateRSense™ 680 (FRS680) blood kinetics by FMT imaging (n = 3 mice) and by serial bleeding (n = 24 mice) showed a high correlation between results. In addition, multiple PK parameters derived from 3-compartment modeling (including $t_{1/2\alpha}$, $t_{1/2\beta}$, $t_{1/2\gamma}$, Volume of distribution, clearance rates, and AUC) were in excellent overall agreement for both methods. Four additional NIR fluorescent-labeled molecules, (a small molecule integrin antagonist, two large vascular agents, and labeled IgG1) were also assessed by FMT heart imaging in comparison to serial bleeds, confirming FMT heart imaging is effective and accurate for determining PK profiles.

The FMT heart imaging technique can work for both small molecule and large molecule PK assessment, however the best applications of this technique are 1) assessing the PK of large molecule biologics in which the size is not significantly changed by the addition of the fluorescent label (e.g. IgGs & large therapeutic proteins) and 2) assessing the PK of NIR fluorescent conjugates of any size (e.g. for imaging probe characterization, blood kinetic applications, & developing drug-delivery conjugates). For the second type of approach, we identified a unique probe/application that can benefit from a non-invasive heart tomography approach, glomerular filtration rate (GFR) measurement using 6 kDa NIR fluorescent-labeled inulin (GFR-Vivo™ 680 [GFR680]). The rate of disappearance of inulin from the blood is directly proportional to GFR, and changes in GFR can indicate kidney dysfunction due to disease or drug-induced injury. Following an intravenous bolus of NIR fluorescent-inulin in hairless SKH-1E mice, longitudinal FMT heart quantification was used to determine blood clearance rates using a two-compartment curve fit, yielding average rates of 240 ± 21 $\mu\text{l}/\text{min}$ in normal mice in close agreement with published GFR data (Qi et al., 2004; Qi et al., 2005; Bivona et al., 2011; Rieg, 2013). Removal of one kidney, or treatment of mice with CsA, both yielded predictable and quantitative delays in GFR of around 50%. These studies showed accompanying increases in plasma creatinine and blood urea nitrogen (BUN), although as expected they did not correlate well with the magnitude of GFR changes. GFR680, in

JPET # 257071

combination with FMT heart imaging, provides a non-invasive fluorescent imaging approach to generate consistent GFR measurements in models of kidney disease, dysfunction, and drug-induced injury.

MATERIALS AND METHODS

Ethics statement

All experiments were performed in accordance with PerkinElmer guidelines based on recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The study protocol was approved by PerkinElmer's (*In Vivo* Imaging Division) IACUC guidelines for animal care and use. Uninephrectomized mice received appropriate surgical procedures at Charles River (Wilmington, MA) 3 days prior to shipping to PerkinElmer for use on day 7. All imaging activities were performed under appropriate anesthesia to minimize animal distress, and no invasive or surgical procedures were used at PerkinElmer in these imaging studies.

Experimental animals

For pharmacokinetic studies, specific pathogen-free BALB/c, SKH-1E, and uni-nephrectomized SKH-1E female mice (6-8 weeks of age) were obtained from Charles River (Wilmington, MA), housed 5 per cage with nesting material, and maintained in a controlled environment (72°F; 12:12-h light-dark cycle) under specific-pathogen free conditions with water and low fluorescence chow (Envigo, Cambridgeshire, United Kingdom) provided ad libitum.

Fluorescent probes and protein conjugates

Commercially available near infrared imaging probes and custom conjugates (PerkinElmer Inc., Waltham, MA) were used to optimize and perform PK studies (summarized in Table 1). All probes were dosed at 2 nmol/mouse (by fluorescence) intravenously according to manufacturer's instructions. FolateRSense™ 680 (FRS680 [Cat. # NEV10040EX]) is a folate-based imaging probe that detects folate receptor expression, AngioSense® 680EX and 750EX (AS680 [Cat. # NEV10054EX] and AS750, [Cat. #

JPET # 257071

NEV10011EX]) are vascular imaging probes; IntegriSense™ 750 (IS750 [Cat. # NEV10873]) detects regions of upregulated $\alpha V\beta 3$ integrin expression associated with cancer, angiogenesis, and other indications; GFR-Vivo 680 (GFR680 [Cat. # NEV30000]) is an NIR-fluorescent labeled inulin molecule used to assess glomerular filtration rate calculated from blood clearance kinetics; VivoTag® 680XL (VT680XL [Cat. # NEV11119]) is an NIR fluorophore that can be used to label large molecule therapeutic proteins and antibodies for biodistribution and PK assessment.

A custom IgG1-fluorophore conjugate was produced using murine IgG1 purchased from Rockland (Gilbertsville, PA) to provide a reference agent for pharmacokinetics studies. N-hydroxysuccinimide (NHS)-ester labeling of proteins was performed using a 680 nm fluorophore (VivoTag 680XL). Briefly, the NHS ester moiety of VT680XL reacts with primary amino groups of proteins to form an amide bond (pH 7 for 1h at room temperature). In this manner, a small number of lysine residues (generally 1 to 2) for antibodies and other proteins can be labeled with fluorophore. Free fluorophore is removed by size exclusion chromatography. Conjugation ratios were easily assessed by measuring absorbance of the conjugates at 280 and 680 nm with appropriate extinction coefficients to determine protein and fluorophore concentration, respectively. Labeling for IgG1 (IgG1-VT680XL) achieved ~2 fluorophores per protein molecule, and this conjugate was dosed in animals at 2 nmol of fluorescence/mouse intravenously. This conjugate showed excellent stability when stored at 4°C and, upon *in vivo* injection, showed no evidence of unconjugated free fluorophore.

***In vivo* PK imaging and blood PK**

Fluorescence imaging requires removal of hair from experimental animals for optimal results, so prior to the imaging, BALB/c mice were anesthetized with isoflurane gas, and hair removed using depilatory cream (Nair, Church & Dwight Co., Ewing, NJ). Briefly, the cream was applied 2–3 times (4–5 min each time) with gentle rinsing in warm water. Hairless SKH1-E mice, or depilated BALB/c mice, were injected intravenously with 2 nmol of NIR fluorescent probes/conjugates and imaged at 5-8 selected time points following injection, the first time being within the first 5 minutes for standard PK studies. For the

JPET # 257071

specific application of GFR assessment, precise timing was critical (with the first image acquisition initiated precisely at 1 min after GFR680 injection) because of the rapid clearance of this probe. At the time of imaging, mice were anesthetized by inhalation in a chamber containing a mixture of isoflurane and oxygen then imaged using the FMT 4000 *in vivo* imaging system (PerkinElmer Inc., Waltham, MA). For heart region imaging, the anesthetized mice were placed in the supine position, centrally in the imaging cassette, to capture the thoracic region of the animal within the imaging scan field (30-40 scan points, ~ 2-minute scan). After positioning the mouse, the imaging cassette was adjusted to the proper depth to gently restrain the mouse and then inserted into the heated docking system (regulated at ~37°C) in the FMT imaging chamber. An appropriate NIR laser diode transilluminated each mouse's body (*i.e.* passed light through the body of the animal to be collected on the opposite side), with signal detection occurring via a thermoelectrically cooled CCD camera placed on the opposite side of the imaged animal. Appropriate optical filters allowed the collection of both fluorescence and excitation datasets, and the multiple source-detector fluorescence projections were normalized to the paired collection of laser excitation data.

Separate non-imaged cohorts of animals were bled for microplate fluorescence assay and quantification of the amount of fluorescent-labeled conjugates. Cohorts were used for terminal blood collection at 5-8 selected times to align with imaging data. Briefly, mice were anesthetized using isoflurane gas, and blood was collected through the retro-orbital plexus using glass capillary tubes. Blood was collected into EDTA- or heparin-coated blood collecting tubes for generation of plasma samples. Control plasma was collected to generate a fluorescent standard curve for comparison to collected samples from experimental mice. The standard curve samples and blood collection samples were also diluted 1:2 in DMSO, which assured the maximal capture of fluorescence despite the presence of proteins that could potentially alter fluorescent signal.

FMT reconstruction and analysis

The collected fluorescence data was reconstructed by FMT 4000 system software (TrueQuant 4.0, PerkinElmer Inc., Waltham, MA) which compensates for the effects of tissue heterogeneity on light scattering (Mohajerani et al., 2009), allowing for the quantification and 3D visualization of fluorescence signal within the heart. Three-dimensional regions of interest (ROIs) were drawn to encompass heart signal within the thoracic region. The total amount of heart fluorescence (in pmol) was automatically calculated relative to prior calibration generated with known concentrations of appropriate NIR dyes. To prevent loss of low-level fluorescence following dissemination of agents into tissues, no thresholding of fluorescence datasets was applied.

PK Analysis

To determine the blood PK profile of a fluorescent conjugate in living mice, unthresholded heart tomography quantification by TrueQuant software was used. To avoid partial volume effects of fluorescence tomography (i.e. some enlargement of target size due to reconstruction voxel size), slightly oversized regions of interest (ROI) were placed to capture total fluorescence per heart (in pmol). This data was converted to nM based on known physiologic parameters; a 25 g mouse has an average of 1.5 ml of blood, of which 7% (or ~100 μ l) is in the heart. All data points in pmol were divided by 0.1 ml, to yield nM results for each time point. A dose of 2000 pmol yields a theoretical time zero blood concentration of 1330 nM, i.e. a time zero heart measurement of ~133 total pmol. However, fluorescence quantification could be affected by how well the imaging system is calibrated as well as by the fluorescence behavior of the conjugate itself, i.e. how much the fluorescent signal is affected by blood and plasma.

To simplify the analysis, we used a normalization of the calculated nM data prior to PK analysis that compensates for fluorophore performance (e.g. microenvironment effects on fluorescence output) as well as for potential dosing and mouse size variability. Generally, the earliest possible acquisition time on the FMT 4000 is 1-5 minutes (defined as the time of scan initiation + the midpoint time for the scan [i.e. ~2-6 minutes]), but normalization requires an “extrapolated” C_0 (C_{0E}). In general, the C_{0E} will be higher than

JPET # 257071

C_1 and may differ somewhat from 1330 nM, depending on the overall fluorophore performance and clearance profile. The C_{0E} can be determined by a variety of curve-fitting methods (or even manual linear extrapolation from the first two acquired data points), but we used the PK Solver 2.0 Excel Add-in (PK Solver) to determine C_{0E} . Normalization of the measured data curves based on mathematical correction of the C_{0E} to the calculated C_0 provided improvements in data robustness when again analyzed by PK Solver. Briefly, for normalization all data points for an individual animal are multiplied by 1330 and divided by C_{0E} , yielding that mouse's PK curve that now starts at a C_0 value of 1330 nM and has the appropriate changes over time. This process is repeated for all the other individual mice. Normalized curves (individual or means of all animals) can be analyzed using any PK software. For our analyses we used PK Solver, choosing non-compartmental or compartmental analyses based on best fit of the data points. For consistency, identical normalization procedures were performed on blood fluorescence microplate data.

GFR Analysis

PK analysis for GFR680, which is very rapidly cleared (<1 min blood $t_{1/2}$), required a more challenging imaging procedure and quantitative approach, which was possible because GFR680 shows little in vivo alteration of fluorescence emission. Analysis relied on the accuracy of FMT quantification values rather than normalization, which means that very precise calibration of the system was essential. Scan fields were established that kept acquisition time to 2 minutes (i.e. use of approximately 30 scan points encompassing the thoracic region). The first 2-minute image acquisition was initiated immediately following probe injection. The optimal time points for scan initiation were 1, 5, 14, 29, and 44 minutes, with actual time points defined as the initiation time plus the mid-point of each two-minute scan (i.e. 2, 6, 15, 30, and 45 minutes). For analysis, slightly oversized regions of interest (ROI) were placed around the heart to assure the capture of all heart fluorescence. As described above, total heart pmol values were again used (rather than nM values) to avoid partial volume effects. All heart pmol values were divided by 0.1 ml to yield concentration in nM. For PK/clearance analysis, a calculated t_0 was set as 1330 nM, and, for a normal mouse, a 50-60% decrease was expected at $t = 1$ minute relative to t_0 . Since the clearance of

JPET # 257071

inulin is so rapid, it was important to include the calculated time zero concentration (1330 nM) to achieve good and consistent calculation of clearance results. A two-compartment curve-fit and analysis generally worked very well and provided clearance values consistent with reports in the literature for normal female mice of this age/size, ranging from 200-300 $\mu\text{l}/\text{min}$. Other mouse strains may or may not differ, but they will be internally consistent based on strain/sex/size. Although GFR680 fluorescence appears to be unaffected by blood, providing objectively accurate quantification in a properly calibrated FMT system, re-calibration or manual data adjustment of the FMT can be performed to assure achieving appropriate GFR values in normal control mice.

PK assessment by microplate assay

SKH1-E or BALB/c female mice were injected intravenously with 2 nmol of each fluorescent agent. Terminal blood samples were collected by cardiac puncture (using heparinized syringes) from 2-3 mice at each time point following carbon dioxide asphyxiation. Blood was diluted 1:2 in DMSO to assure capture of maximal fluorescent signal, and fluorescence was measured using a fluorescence plate reader (Molecular Devices, Sunnyvale, CA). The data was normalized to a standard curve prepared in blood/DMSO with known concentrations of the agent to quantify blood levels in nM concentration. Results were normalized to the first collected time point, which was set as 1330 nM as with the *in vivo* imaging analysis. PK analysis was performed as described above.

***Ex Vivo* plasma creatinine and blood urea nitrogen assays**

Plasma assays for Creatinine (Creatinine Assay Kit MAK080, Sigma-Aldrich, St. Louis MO) and blood urea nitrogen (BUN; QuantiChrom™ Urea Assay Kit DIUR-100, BioAssay Systems, Hayward CA) were performed according to manufacturers' instructions. Briefly, plasma samples were collected from Sham, Uninephrectomy, Vehicle and CsA-treated mice, and they were filtered through a 10 kDa MW cut-off filter. Samples (5 μl) were assayed in duplicate in 96-well plates. Quantification was made in comparison to creatinine and BUN standard curves.

JPET # 257071

Results

A fluorescence tomographic imaging method for measuring heart blood pharmacokinetics. The use of fluorescence tomography to acquire fluorescent heart images and the quantification of NIR fluorescent-labeled agents requires careful mouse preparation, proper study design, consistent animal positioning, and proper analysis to generate robust blood PK data. The first important consideration is to work with hairless or depilated mice (completed hair removal of front, sides, back of thoracic region) to achieve proper transillumination required for tomographic imaging and reconstruction. A second consideration is that a unique laser-based fluorescence tomographic imaging system, e.g. the FMT 4000, is required to get proper 3D imaging of the heart. Thirdly, mice should be injected with no more than 2 nmol of agent (as assessed by fluorescence) to limit blood levels to no more than 1.5 μ M concentrations. This injection dose avoids potential problems with fluorophore autoquenching at concentrations in blood $>2 \mu$ M, i.e. a condition yielding falsely low readings, which would lead to abnormal PK curves and inaccurate quantification.

Figure 1 illustrates the concept of heart tomography PK and proper study design, which requires an initial acquisition time within 5 minutes of injection as well as additional acquisition time points that cover the full range of expected blood clearance kinetics. At t_0 , 100% of the injected conjugate is in the blood, including the heart, allowing a reference time point of objectively known blood concentration. As the heart of a 25 g mouse is known to contain 7% of the circulating blood, this makes it a useful location to non-invasively assess blood fluorescence through imaging. The first acquired time point t_1 (recommended as a 1-5 min acquisition time) will show some small decline in signal, the magnitude of which depends on the clearance kinetics of the specific conjugate, and this reflects the loss of blood signal due to clearance and/or extravasation into tissue. This signal will decrease further over subsequent times, until at the last time (t_n) the heart signal is below detection. To test the application of heart tomography for PK assessment, normal SKH1-E mice received intravenous injections of FRS680 (a folate-based probe that clears quickly through the kidneys), and mice were imaged longitudinally. As shown in Figure

2A, a tomographic scan field was established in the thoracic region, and scanning/reconstruction for $t = 1$ minute (Fig. 2B) reveals an upper torso pattern of heart, carotids/jugular veins, and the upper liver vasculature. An ellipsoidal ROI placed to capture the 3-dimensional heart, shows accurate localization of the heart in the appropriate position in the mice. The complete array of longitudinal tomographic images from 1 min to 24 h (Fig. 2C) illustrates the kinetic changes in heart blood levels.

Quantitative assessment of the FRS680 imaging dataset, performed as described in the Materials & Methods section, was compared to blood fluorescence measured using microplate assays of sequential bleeds of a much larger cohort ($n = 30$) of FRS680-injected mice. Graphing of the PK data (Figs. 3A & 3B) confirmed very similar curves for non-invasive imaging and blood assays ($r^2 = 0.96$), and comparison of various PK parameters (Fig. 3C) using a 3-compartment fit confirmed very similar results in blood half-lives, clearance, volume of distribution (V), and AUCs. The $t_{1/2}$ alpha measurement (2 minutes) was consistent with the major route of clearance through the kidneys, and the $t_{1/2}$ beta (26 vs 23 minutes for heart vs blood, respectively) and $t_{1/2}$ gamma (240 vs 102 minutes) measurements were consistent with some target-specific tissue retention.

Assessment of the blood PK profiles for four additional NIR fluorescent-labeled molecules of various sizes. Four additional fluorescent conjugates, ranging in molecular weights from 1.3 to 150 kDa, were also tested by heart imaging to establish the performance range of FMT heart PK assessment (Fig. 4). PK analysis was performed using noncompartmental, 1-compartment, and 2-compartment curve-fitting to identify the best approach (i.e. the closest fit for the data) for each fluorescent conjugate. Two versions of the vascular probe AngioSense (AS680EX and AS750EX), both 70 kDa and differing only modestly in structure, were measured longitudinally by heart tomography and by serially bleeds. Surprisingly, the two probes differed dramatically (by ~7-10-fold) in clearance rates and blood half-lives, with AS750 showing longer retention *in vivo* ($t_{1/2} = 38$ h vs 4 h for AS680). In comparing the two methods for PK assessment the curves were quite similar despite using only 3 mice per probe for heart imaging (with all time points acquired in each mouse), whereas 12 or 15 mice were used for blood assays

(terminal bleeds of 3 mice for each time point). For both probes there were excellent correlations between heart imaging and direct blood assay when comparing the PK curves ($r^2 > 0.90$) as well as when comparing analytical readouts like half-life, AUC, CL, and Vss ($r^2 = 0.99$). The 1.3 kDa probe IS750 showed some minor difference when comparing heart imaging and direct blood assessment, with PK parameters differing by roughly 2-fold, although PK curves correlated well and differed in half-life only by 30 minutes. Application of the two PK assessment methods to NIR fluorescent-labeled control mouse IgG1 (~150 kDa) yielded very similar results with high correlations of curves and various PK measures.

Measuring glomerular filtration rate using GFR680 heart PK imaging. Clinicians mostly rely on indirect calculation of GFR based on plasma creatinine, however direct GFR measurement (quantifying clearance of injected inulin) is the gold standard for detecting kidney changes associated with drug-induced injury or disease. The rate of clearance of labeled inulin from the blood is equivalent to the filtration rate at the kidneys' glomeruli, as there is no subsequent tubular reabsorption. GFR measurement relies on two established approaches; 1) continuous inulin intravenous infusion with timed urine collection, or 2) a single bolus intravenous injection with timed blood collection (Qi and Breyer, 2009). The first approach in mice is impractical, difficult to achieve steady-state plasma levels, and can overestimate GFR due to the potential for non-renal clearance of inulin that arises with continuous infusion (Orlando et al., 1998). The second approach is simple and practical with little or no contribution of non-renal clearance, but it requires collection of several timed blood samples, which can require multiple cohorts of mice for preclinical application.

We have developed an NIR fluorescent-labeled form of inulin (GFR680) for *in vivo* use in mouse intravenous bolus GFR measurement. Figure 5 shows an experiment used to characterize GFR680 performance, focusing on heart imaging for the purposes of PK measurement, but including kidney tomography and 2D epifluorescence imaging of bladder signal to better understand clearance behavior. FMT scans of the heart (Fig. 5A, left image) were used to detect and quantify blood levels of GFR680 at multiple time points following a bolus intravenous injection of 2 nmol of probe. Following the injection

JPET # 257071

in 5 normal SKH-1E mice, FMT images were acquired at 2, 6, 15, 30, and 45 minutes post-injection (Fig. 5B, upper panel). Clearance rates for the 5 mice in this study were calculated using a two-compartment curve fitting, yielding an average rate of 240 ± 50 $\mu\text{l}/\text{min}$ in this study in normal mice (Fig. 5C). We examined the possibility of using either kidney tomography (Fig 5A, right image) or bladder epifluorescence imaging (Fig. 5A, left image) as potential methods to more easily assess GFR680 clearance as single timepoint acquisitions. Although both kidney and bladder signal generally increased over time in most mice (Fig. 5B, middle & lower panels), the absolute amounts of fluorescence were highly variable between animals and were impacted substantially by bladder voiding. Figure 5D shows that 2 of 5 mice lost most of their kidney fluorescence due to bladder voiding early in the imaging process. These two mice also were delayed or lower in bladder signal (Fig. 5E). Figure 5F represents a tabular summary of five separate studies measuring GFR using heart tomography, showing an average GFR value for normal mice at 240 $\mu\text{l}/\text{min}$ with around 8% inter-assay variability. This average value falls within the typical range of published mouse inulin-based assessment of GFR values in anesthetized mice ($229 - 325$ $\mu\text{l}/\text{min}$) as summarized by Qui and colleagues (Qi et al., 2004). A subset of our heart tomography data was also compared to timed *ex vivo* blood assays (assessed by microplate assays) of mice receiving either GFR680 or Inulin-FITC (Supplemental Figure S1), with excellent correlations of heart tomography to microplate assays (Fig. 5F).

Validating heart tomography GFR method in unilaterally nephrectomized (UNX) mice. After establishing normal ranges of GFR determined by heart tomography, it was important to validate this assay by altering GFR in a defined manner. Surgical removal of a single kidney has an expected dramatic effect on overall kidney filtration that has been studied in both experimental animals and humans. The remaining kidney undergoes compensatory changes, including hypertrophy and/or hyperplasia of glomeruli and tubules, increased metabolic activity, and an increase in urinary output, over time resulting in improved glomerular filtration (Fine, 1986). In UNX rats, the expected 50% decline in GFR is

followed by some functional compensation after 2 days, leading to only a 25% deficiency in GFR over the long term (Chamberlain and Shirley, 2007). In mice, however, GFR declines by 50% immediately following UNX but recovers very little over 52 weeks to approximately 41% deficiency (Jani et al., 2006). This suggests that functional kidney measurements within 1 week in UNX mice would reflect near maximal loss of GFR function.

To assess our heart imaging methodology, unilaterally nephrectomized SKH1-E female mice were imaged (7 days post-uninephrectomy) at 2, 6, 15, 30, and 45 minutes using GFR680, and the calculated clearance rates were compared to normal (Sham surgery) mice. Figure 6A shows heart region tomographic images over time, illustrating obvious differences at most time points. Graphical representation of TrueQuant quantification for both individual mice (Fig. 6B) and group averages (Fig. 6C) reveals a clear impairment or slowing of clearance kinetics with statistical differences observed at 15, 30 and 45 minute times. Clearance rates derived from these curves determined a 52% decrease in UNX group GFR relative to that of Sham controls (Fig. 6D), with accompanying more modest changes (~1.5x increases) in plasma creatinine and BUN (Fig. 6E).

Measuring CsA-induced impairment of GFR. CsA is well characterized for its ability to cause kidney injury, inducing acute and chronic renal dysfunction, hemolytic-uremic syndrome, hypertension, tubular acidosis, juxtaglomerular apparatus hypertrophy and hyperplasia, increased kidney renin, and progressive renal interstitial fibrosis (Burdmann et al., 2003). We used CsA treatment of mice based on the protocol of Puigmule et al (Puigmule et al., 2009) as another means to validate FMT heart tomography for assessing GFR changes. Briefly, female SKH-1E mice were injected subcutaneously with CsA (80 mg/kg/day) or vehicle (olive oil) once per day for 14 days. Mice were then injected intravenously with 2 nmol of GFR680, and the heart of each animal was imaged at 2, 6, 15, 30, and 45 minutes by fluorescent tomography. Graphical representation of TrueQuant quantification (Fig. 7A) shows impairment of GFR as a clear curve shift in blood fluorescence kinetics. Clearance rates derived from these curves determined a 47% decrease in the CsA group GFR relative to that of Vehicle controls

JPET # 257071

(Fig. 7B), and there were also significant changes (~2.5x increases) in plasma creatinine and BUN (Fig. 7C).

Discussion

Fluorescence optical imaging remains a young imaging modality, but has capabilities that can support a wide range of preclinical therapeutic areas of research (Kossodo et al., 2010; Peterson et al., 2010; Ackermann et al., 2011; Zhang et al., 2012; Felix et al., 2015; Peterson, 2016; Vasquez and Peterson, 2017). Advances in photonic technology and reconstruction algorithms (Meyer et al., 2007; Lasser et al., 2008; Mohajerani et al., 2009; Mohajerani and Ntziachristos, 2016) have even taken optical imaging beyond standard 2D epifluorescence imaging into the realm of 3D tomographic imaging for localization and quantification of fluorescence in deep tissue. This has opened the door to more challenging imaging applications, including brain, heart, liver and lung imaging (Korideck and Peterson, 2009; Clapper et al., 2011; Lin et al., 2012; Eaton et al., 2013). Co-registered tomographic FMT and PET datasets agreed very well spatially and quantitatively (Nahrendorf et al., 2010), supporting the accuracy of FMT imaging as a non-radioactive surrogate for preclinical PET imaging applications. Indeed, one of the most important PET imaging applications, whole body biodistribution, is a method that was established in 2011 as a robust FMT application (Vasquez et al., 2011) with large and small fluorescent agents showing differential kinetics of fluorescence distribution to, and clearance from, major tissues and organs. Subsequent mouse studies determined that tomographic heart fluorescence results generally correlated quite well with blood PK assessment, however epifluorescence approaches in mice (heart, superficial veins, eyes) were poor or almost completely ineffective (Peterson et al., unpublished observations). This means that fluorescence heart tomography is a useful optical approach to the non-invasive assessment of blood PK, offering some clear benefits in reduction of animals and/or improved ease of use as compared to other imaging and non-imaging approaches.

The data in this report examines fluorescent conjugates from 1.3 to 150 kDa molecular weights, with comparable PK results seen in parallel heart tomography and serial bleed assays (Figs. 2, 3, & 4). The imaging approach offers two advantages over microplate assays: 1) full kinetic curves for each individual animal and 2) the ability to use only 3-5 mice. There are also some advantages of this imaging approach over blood microsampling approaches, which can also decrease animal use, in that there is no sample

collection, manipulation, or additional analytical acquisition required. Data is generated from the heart imaging datasets using simple analysis tools. The major application for FMT technology in PK imaging is likely to be assessing antibodies or large protein therapeutics, since the NIR fluorophore reporters used tend to be large (~1,000 Da) but would have minimal effect on the size of high molecular weight proteins like antibodies. Indeed, a preliminary report has shown that heart tomography with NIR fluorescent-labeled therapeutic antibodies can generate useful PK readouts (Giddabasappa et al., 2016). In contrast, NIR fluorophore conjugation significantly increases the size of small molecule drugs, which would then likely result in altered PK and biodistribution (i.e. generating data not easily extrapolated to the unconjugated parent molecule). However, even for large proteins, researchers must take care to not over-label with fluorophores, which can risk changing the PK of the parent molecule. In general, a 1-to-1 labeling ratio works well, but we are also currently exploring lower molecular weight NIR fluorophores to further minimize potential PK-altering conjugation effects.

A second important use of FMT heart imaging, applicable to imaging probes of any size, is fluorescent probe development and characterization, in which the conjugate itself is the relevant agent being studied. Understanding PK is essential in probe design as well as in determining earliest possible imaging windows. Some imaging applications for fluorescent probes may also benefit from PK assessment, for example correcting biodistribution imaging data to better understand vascular contribution vs tissue extravasation at sites of interest (Vasquez et al., 2011). For vascular probes, kinetic imaging with blood level correction can add another dimension to understanding vascularity, vascular damage, edema, and angiogenesis in a variety of inflammatory or disease states. Rates of tissue extravasation and clearance in some instances may more sensitively characterize physiological changes in tissue (e.g. in treatments affecting edema or angiogenesis).

Lastly, PK assessment of labeled inulin (Figs. 5, 6, & 7) offers a very unique approach to assessing damage-induced alterations in glomerular filtration rate (Qi et al., 2004; Qi et al., 2005; Bivona et al., 2011; Rieg, 2013), and non-invasive heart tomography of an NIR fluorescent-labeled inulin, in particular, offers the advantage of requiring very few mice. The best use of this mouse GFR method is likely in early

JPET # 257071

drug discovery, providing early risk assessment to help to prioritize research on compounds with good safety profiles. Our heart imaging approach here has been validated using both a uninephrectomy model and CsA-induced kidney injury, with additional comparison to conventional plasma creatinine and BUN assays. The results for normal GFR are consistent with numbers reported in the literature data (Qi et al., 2004; Qi et al., 2005; Bivona et al., 2011; Rieg, 2013). It is interesting to note that we did not observe obvious GFR compensation in unilaterally nephrectomized mice at 7 days (which theoretically should have shown as less than 50% GFR inhibition if compensation was occurring), however the timing of GFR compensation post-uninephrectomy in mice has not been characterized. A similar GFR-alteration (45% decrease) was seen with 2 weeks of CsA-dosing, and some additional preliminary studies suggest a greater magnitude of GFR inhibition at early time points (Peterson, unpublished observations), suggesting that some GFR compensation may occur later despite ongoing treatment. Further studies are in progress to examine the effects of other drugs as well as the kinetics of kidney compensatory functional recovery following tissue injury. The heart imaging method is not only amenable to kinetic imaging to assess GFR, but can also be used in a longitudinal fashion, i.e. repeated injection of GFR680 (with kinetic imaging) over many days of drug dosing. Unfortunately, due to the challenges of fluorescent tomography, it is not possible to perform heart imaging studies in rats. This is a significant limitation, however future advances in the technology will likely enable rat GFR assessment by fluorescent imaging, which could offer significant advantages over microCT (which involves known kidney toxicity of contrast agents) and DBS (labor intensive analysis) for measuring kidney function.

In conclusion, we have demonstrated the ability of non-invasive FMT heart imaging to visualize and quantify blood pharmacokinetics in a robust and consistent manner with the need for very few animals. The consistency of the quantitative tomography, as well as its excellent correlation with *ex vivo* assessment of blood kinetics, provides a powerful tool for assessing large molecular weight biotherapeutics and various novel imaging probes. Application of this method to GFR680 provides a non-invasive approach to GFR measurements in models of kidney disease, dysfunction, and drug-induced injury.

JPET # 257071

JPET # 257071

Authorship Contributions

Participated in research design: Bao, Vasquez & Peterson

Conducted experiments: Bao, Vasquez, Zhang

Contributed new reagents or analytic tools: Ho, Delaney & Peterson

Performed data analysis: Bao & Peterson

Wrote or contributed to the writing of the manuscript: Bao, Vasquez, Rajopadhye &
Peterson

References

- Ackermann M, Carvajal IM, Morse BA, Moreta M, O'Neil S, Kossodo S, Peterson JD, Delventhal V, Marsh HN, Furfine ES and Konerding MA (2011) Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. *Int J Oncol* **38**:71-80.
- Balls M (2015) 16. The Three Rs: the way forward. *Altern Lab Anim* **43**:P25-27.
- Bivona BJ, Park S and Harrison-Bernard LM (2011) Glomerular filtration rate determinations in conscious type II diabetic mice. *Am J Physiol Renal Physiol* **300**:F618-625.
- Burdmann EA, Andoh TF, Yu L and Bennett WM (2003) Cyclosporine nephrotoxicity. *Semin Nephrol* **23**:465-476.
- Chamberlain RM and Shirley DG (2007) Time course of the renal functional response to partial nephrectomy: measurements in conscious rats. *Exp Physiol* **92**:251-262.
- Clapper ML, Hensley HH, Chang WC, Devarajan K, Nguyen MT and Cooper HS (2011) Detection of colorectal adenomas using a bioactivatable probe specific for matrix metalloproteinase activity. *Neoplasia* **13**:685-691.
- Eaton VL, Vasquez KO, Goings GE, Hunter ZN, Peterson JD and Miller SD (2013) Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo. *J Neuroinflammation* **10**:138.
- Felix DD, Gore JC, Yankeelov TE, Peterson TE, Barnes S, Whisenant J, Weis J, Shoukouhi S, Virostko J, Nickels M, McIntyre JO, Sanders M, Abramson V and Tantawy MN (2015) Detection of breast cancer microcalcification using (99m)Tc-MDP SPECT or Osteosense 750EX FMT imaging. *Nucl Med Biol* **42**:269-273.
- Fine L (1986) The biology of renal hypertrophy. *Kidney Int* **29**:619-634.
- Giddabasappa A, Gupta VR, Norberg R, Gupta P, Spilker ME, Wentland J, Rago B, Eswaraka J, Leal M and Sapra P (2016) Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography. *Mol Cancer Ther* **15**:2530-2540.
- Jani A, Wang W, Faubel S, Falk S, Ljubanovic D, Dursun B and Edelstein CL (2006) Ischemic acute renal failure following nephrectomy impairs long-term renal function. *Transplantation* **81**:800-803.
- Korideck H and Peterson JD (2009) Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. *J Pharmacol Exp Ther* **329**:882-889.
- Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, Jensen J, Hargreaves R, Coleman P, Hartman G, Rajopadhye M, Duong LT, Sur C, Yared W, Peterson J and Bednar B (2010) Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). *Mol Imaging Biol* **12**:488-499.
- Lasser T, Soubret A, Ripoll J and Ntziachristos V (2008) Surface Reconstruction for free-space 360 degrees fluorescence molecular tomography and the effects of animal motion. *IEEE Trans Med Imaging* **27**:188-194.
- Lin SA, Patel M, Suresch D, Connolly B, Bao B, Groves K, Rajopadhye M, Peterson JD, Klimas M, Sur C and Bednar B (2012) Quantitative Longitudinal Imaging of Vascular

- Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and $\alpha(v)\beta(3)$ Integrin. *Int J Mol Imaging* **2012**:189254.
- Meyer H, Garofalakis A, Zacharakis G, Psycharakis S, Mamalaki C, Kioussis D, Economou EN, Ntziachristos V and Ripoll J (2007) Noncontact optical imaging in mice with full angular coverage and automatic surface extraction. *Appl Opt* **46**:3617-3627.
- Mohajerani P, Adibi A, Kempner J and Yared W (2009) Compensation of optical heterogeneity-induced artifacts in fluorescence molecular tomography: theory and in vivo validation. *J Biomed Opt* **14**:034021.
- Mohajerani P and Ntziachristos V (2016) An Inversion Scheme for Hybrid Fluorescence Molecular Tomography Using a Fuzzy Inference System. *IEEE Trans Med Imaging* **35**:381-390.
- Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, Pivovarov M, Swirski FK, Pittet MJ, Vinegoni C and Weissleder R (2010) Hybrid PET-optical imaging using targeted probes. *Proc Natl Acad Sci U S A* **107**:7910-7915.
- Orlando R, Floreani M, Padriani R and Palatini P (1998) Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers. *Br J Clin Pharmacol* **46**:605-609.
- Peterson JD (2016) Noninvasive in vivo optical imaging models for safety and toxicity testing, in *Nutraceuticals: Efficacy, Safety and Toxicity* (Gupta RC ed) pp 305-317, Academic Press, London.
- Peterson JD, Labranche TP, Vasquez KO, Kossodo S, Melton M, Rader R, Listello JT, Abrams MA and Misko TP (2010) Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. *Arthritis Res Ther* **12**:R105.
- Puigmule M, Lopez-Hellin J, Sune G, Tornavaca O, Camano S, Tejedor A and Meseguer A (2009) Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. *Nephrol Dial Transplant* **24**:2672-2686.
- Qi Z and Breyer MD (2009) Measurement of glomerular filtration rate in conscious mice. *Methods Mol Biol* **466**:61-72.
- Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB and Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. *Diabetes* **54**:2628-2637.
- Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB and Breyer MD (2004) Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. *Am J Physiol Renal Physiol* **286**:F590-596.
- Rieg T (2013) A High-throughput method for measurement of glomerular filtration rate in conscious mice. *J Vis Exp*:e50330.
- Toon S (1996) The relevance of pharmacokinetics in the development of biotechnology products. *Eur J Drug Metab Pharmacokinet* **21**:93-103.
- Vasquez KO, Casavant C and Peterson JD (2011) Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging. *PLoS One* **6**:e20594.
- Vasquez KO and Peterson JD (2017) Early Detection of Acute Drug-Induced Liver Injury in Mice by Noninvasive Near-Infrared Fluorescence Imaging. *J Pharmacol Exp Ther* **361**:87-98.

JPET # 257071

- Zhang J, Preda DV, Vasquez KO, Morin J, Delaney J, Bao B, Percival MD, Xu D, McKay D, Klimas M, Bednar B, Sur C, Gao DZ, Madden K, Yared W, Rajopadhye M and Peterson JD (2012) A fluorogenic near-infrared imaging agent for quantifying plasma and local tissue renin activity in vivo and ex vivo. *Am J Physiol Renal Physiol* **303**:F593-603.
- Zhang Q, Tomazela D, Vasicek LA, Spellman DS, Beaumont M, Shyong B, Kenny J, Fauty S, Fillgrove K, Harrelson J and Bateman KP (2016) Automated DBS microsampling, microscale automation and microflow LC-MS for therapeutic protein PK. *Bioanalysis* **8**:649-659.

JPET # 257071

Footnotes

Financial Support: Support for these studies was provided by internal funds from PerkinElmer Inc. R&D budgets.

FIGURE LEGENDS

Figure 1. Diagrammatic representation of the FMT heart tomography PK model. Mice are injected with NIR fluorescent-labeled agents at time 0 and imaged by FMT immediately, at the time (t_1) when most of the fluorescence is in circulation (as revealed by heart imaging). At defined times thereafter (dependent on the agent being studied), mice are imaged to assess the kinetic changes in heart signal that reflect overall blood pharmacokinetics.

Figure 2. Kinetic imaging of the heart region of SKH1-E mice after FRS680 intravenous injection offers a non-invasive approach to quantifying circulating fluorescence. Female SKH-1E mice ($n = 3/\text{group}$) were injected intravenously with 2 nmol of FRS680, and the heart of each animal was imaged to capture 2, 5, 15, 30, 45, 60, 120, 180 and 1440 minutes by FMT tomography. (A) The representative FMT scan field location and size within the thoracic region for optimal heart fluorescence reconstruction. (B) A representative mouse injected with FRS680 and imaged by FMT 1 minute later yields heart and blood vessel signal (C) Images from a representative FRS680 injected mouse imaged non-invasively by FMT over time to reveal kinetic changes in heart/blood signal.

Figure 3. FRS680 heart PK analysis and comparison to PK assessment by serial bleeds and microplate assay. (A) Quantitative PK curve established non-invasively by FMT heart imaging of SKH1-E mice ($n = 3$) was compared to a parallel study in which multiple cohorts of mice ($n = 30$) were serially bled and samples were assayed *ex vivo* in comparison to a standard curve. (B) Correlation between heart tomography and blood assay results. (C) Various pharmacokinetic parameters were assessed using PK Solver, with (D) a correlation between quantitative PK parameters.

Figure 4. Heart PK analysis of three NIR fluorescent imaging probes and NIR fluorescent-labeled IgG1. In the upper panel is shown quantitative PK curves for three probes established non-invasively by FMT

JPET # 257071

heart imaging of SKH1-E mice ($n = 3$) as compared to parallel studies in which multiple cohorts of mice ($n = 30$) were serially bled and samples quantified ex vivo based on a standard curve. The same comparison was made for IgG1-VivoTag680XL in depilated female BALB/c mice. The lower panel is a tabular summary of various pharmacokinetic parameters that were assessed using PK Solver for both heart imaging and blood assay data.

Figure 5. GFR assessment in normal mice by FMT heart imaging. Normal female SKH-1E mice ($n = 5/\text{group}$) were injected intravenously with 2 nmol of GFR680, and the heart of each animal was imaged over time by FMT 4000 tomography. (A) Ventral and dorsal imaging strategies illustrating position and size of tomographic scan field for the heart (left) and kidneys (right). Parallel acquired ventral epifluorescence was used to measure bladder signal (left). (B) Representative images of heart tomography (upper), kidney tomography (middle), and bladder epifluorescence (lower), showing the kinetic change in fluorescence in these regions. (C) Quantitative PK graph of data established non-invasively by FMT heart imaging of SKH1-E mice, showing each individual mouse's blood PK curve. GFR was determined using 2 compartment fits for each mouse using PK Solver. (D) Quantitative kidney fluorescence kinetics established non-invasively by FMT imaging. (E) Quantitative bladder epifluorescence kinetics established non-invasively by 2D imaging in units of fluorescent counts per energy (C/E). (F) Tabular summary of results from 5 studies in normal mice, showing average group results and interassay coefficient of variation (CV).

JPET # 257071

Figure 6. Unilateral nephrectomy-induced effects on kidney GFR function. Seven days following uninephrectomy, female SKH-1E mice ($n = 3/\text{group}$) were injected intravenously with 2 nmol of GFR680 and the heart of each animal was imaged over time by FMT 4000 tomography. (A) Heart tomography images from representative Sham and UNX mice, illustrating obvious differences in the clearance kinetics. (B) Line graphs of heart fluorescence kinetics for each individual Sham and UNX mouse. (C) Line graphs for group averages of Sham and UNX mice with curve fitting. (D) Clearance rates for each group, based on FMT heart PK were calculated using PK Solver. (E) Plasma creatinine and BUN were assessed, revealing modest UNX-induced increases. Asterisks and hatchmarks indicate statistically significant differences between Sham and UNX groups ($\#p < 0.05$; $*p < 0.01$). Dotted lines highlight the basal background levels for creatinine and BUN based on the Sham control group.

Figure 7. CsA-induced effects on kidney GFR function. Female SKH-1E mice ($n = 5/\text{group}$) were treated with 100 μl CsA (80 mg/kg/day formulated in olive oil) or vehicle (olive oil) injected subcutaneously for 14 days. Mice were then injected intravenously with 2 nmol of GFR680 and the heart of each animal was imaged at 1, 5, 15, 30, and 45 minutes by FMT 4000 tomography. (A) Average heart levels of GFR680 in Vehicle- and CsA-treated mice. (B) Average calculated GFR for each group. (C) Plasma creatinine and BUN were assessed, revealing CsA-induced increases. Asterisks and hatchmarks indicate statistically significant differences between Vehicle and CsA groups ($\#p < 0.05$; $*p < 0.01$). Dotted lines highlight the basal background levels for creatinine and BUN based on the Vehicle group.


JPET # 257071

1

	MW (kDa)	Description	Ex/Em	Applications
FolateRSense™ 680 (FRS680)	1.6	Folate-based NIR fluorescent imaging probe	670/690	Oncology and inflammation
AngioSense® 680EX (AS680)	70	NIR fluorescent labeled PEG-polylysine copolymer used as a vascular imaging probe	670/690	Vascularity and vascular leak changes in oncology and inflammation
AngioSense® 750EX (AS750)	70	NIR fluorescent labeled PEG-polylysine copolymer used as a vascular imaging probe	750/770	Vascularity and vascular leak changes in oncology and inflammation
IntegriSense™ 750 (IS750)	1.28	NIR fluorescent labeled small molecule αVβ3 integrin antagonist	755/775	Oncology, atherosclerosis, angiogenesis
GFR-Vivo™ 680 (GFR680)	~6.0	NIR fluorescent labeled inulin	670/690	Measuring glomerular filtration rate (GFR) by blood pharmacokinetics
IgG1-VivoTag® 680XL (IgG1-VT680XL)	150	Normal mouse IgG1 labeled with VivoTag 680XL	665/688	Control

FIGURE 1


Non-invasive Pharmacokinetics Assessment by Heart Fluorescence Tomography




JPET # 257071

FIGURE 2

A. Scan Field



B. Heart ROI Placement



C. Heart Imaging Time Course






FIGURE 3

A. PK Measurement Approaches




B. PK Method Correlation



C. PK Parameters (Heart Imaging vs Blood Assay)

Parameter	Unit	Heart	Blood
$t_{1/2\text{Alpha}}$	min	2	2
$t_{1/2\text{Beta}}$	min	26	23
$t_{1/2\text{Gamma}}$	min	240	102
C0	nM	1362	1376
V	ml	1.5	1.5
CL	ml/min	0.023	0.034
V2	ml	1.3	3.3
CL2	ml/min	0.224	0.36
V3	ml	3.6	0.0
CL3	ml/min	0.035	0
AUC 0-t	nM*min	4.6E+04	4.3E+04
AUC 0-inf	nM*min	8.7E+04	6.0E+04
AUMC	nM*min ²	2.41E+07	8.42E+06
MRT	min	279	141
Vss	ml	6.5	4.7

FIGURE 4



Specificity	Vascular Probe 70 kDa 1 Compartment		Vascular Probe 70 kDa Noncompartmental		$\alpha V\beta 3$ Integrin Probe 1.28 kDa 1 Compartment		Immunoglobulin 150 kDa Noncompartmental	
Molecular Weight	Heart	Blood	Heart	Blood	Heart	Blood	Heart	Blood
PK analysis Model	Heart	Blood	Heart	Blood	Heart	Blood	Heart	Blood
$t_{1/2}$ (h)	4.4	6.3	37.8	43.9	1.0	0.5	46.7	38.5
AUC 0-t (pmol/ml*h)	7824	11305	41785	43670	1764	893	53608	37691
CL (μ l/min)	4.2	2.8	0.5	0.4	18.7	37.3	0.5	0.7
Vss (ml)	1.6	1.5	1.5	1.5	1.7	1.6	1.6	1.7

FIGURE 5






FIGURE 6


A. FMT Heart Fluorescence Images




B. Individual Heart Data




C. Average PK Profiles



D. GFR (clearance rate)




E. Creatinine and BUN



JPET # 257071

FIGURE 7



Blood Pharmacokinetics Imaging by Non-invasive Heart Fluorescence Tomography and Application to Kidney Glomerular Filtration Rate Assessment

Bagna Bao, Kristine O. Vasquez, Guojie Ho, Jun Zhang, Jeannine Delaney, Milind Rajopadhye, and Jeffrey D. Peterson

Supplemental Figures




Figure S1. Five SKH1-E mice were injected with GFR-Vivo 680 for FMT4000 heart PK assessment. Thirty SKH1-E mice were injected with GFR-Vivo 680, and an additional 30 mice were injected with FITC-Inulin (Sigma-Aldrich), for plasma collection and microplate measurement of fluorescence. Each dataset represents a sequence of time points including 1, 5, 15, 30, 45, 60, 90, 120, 150, and 180 minutes. Left panel compares plasma GFR-Vivo microplate results with heart imaging data, and the right panel compares plasma GFR-Vivo microplate results with plasma FITC-Inulin microplate results. The top concentration data point from the FITC-Inulin microplate results was excluded as an outlier due to apparent fluorescence quenching.